BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35169086)

  • 1. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
    Sasaki N; Nagane M
    No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphomas of Central Nervous System.
    Yokogami K; Azuma M; Takeshima H; Hirai T
    Adv Exp Med Biol; 2023; 1405():527-543. PubMed ID: 37452952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
    Steffanoni S; Batchelor TT
    Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of Primary Central Nervous System Lymphoma: Standard Treatments According to the Japanese 2019 Guideline and Novel Treatments].
    Sasaki N; Nagane M
    Brain Nerve; 2021 Oct; 73(10):1107-1114. PubMed ID: 34615748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary central nervous system lymphoma: Novel precision therapies.
    Mondello P; Mian M; Bertoni F
    Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
    Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary central nervous system lymphoma.
    Schaff LR; Grommes C
    Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Schaff L; Nayak L; Grommes C
    Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
    Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
    Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
    Roschewski M; Hodson DJ
    Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Apr; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
    Zou R; Zhou X; Liu H; Wang P; Xia F; Kang L; Yu L; Wu D; Jin Z; Qu C
    Cancer Res Treat; 2023 Oct; 55(4):1363-1368. PubMed ID: 37321275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.
    Mendez JS; Grommes C
    Am Soc Clin Oncol Educ Book; 2018 May; 38():604-615. PubMed ID: 30231317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
    Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
    Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.